234,934 Shares in Bruker Co. (NASDAQ:BRKR) Purchased by Eversept Partners LP

Eversept Partners LP purchased a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 234,934 shares of the medical research company's stock, valued at approximately $13,772,000. Bruker accounts for about 1.2% of Eversept Partners LP's investment portfolio, making the stock its 17th largest holding. Eversept Partners LP owned 0.15% of Bruker at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Eagle Bay Advisors LLC grew its position in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after purchasing an additional 248 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after purchasing an additional 412 shares in the last quarter. Quadrant Capital Group LLC raised its stake in Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Bruker by 41.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after purchasing an additional 390 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Trading Up 0.3 %

Shares of Bruker stock traded up $0.10 on Friday, hitting $39.07. The stock had a trading volume of 1,647,373 shares, compared to its average volume of 1,520,537. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a one year low of $34.10 and a one year high of $82.04. The stock's 50-day simple moving average is $43.22 and its two-hundred day simple moving average is $52.62. The stock has a market cap of $5.92 billion, a price-to-earnings ratio of 51.41, a PEG ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, sell-side analysts predict that Bruker Co. will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.51%. Bruker's dividend payout ratio is currently 26.32%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BRKR. Wells Fargo & Company decreased their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Guggenheim reissued a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Citigroup dropped their price target on Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Barclays reduced their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, Stifel Nicolaus dropped their target price on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $65.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.